| Drug General Information |
| Drug ID |
D0Z8EX
|
| Drug Name |
Stavudine |
|
| Synonyms |
DdeThd; DdeTyd; Dideoxydidehydrothymidine; Estavudina; STV; Sanilvudine; Stavudinum; Zent; Zerit; Zerit Xr; Zerut XR; BMY 27857; BMY27857; D 1413; D 4T; BMY-27857; Bristol-Myers Brand of Stavudine; Bristol-Myers Squibb Brand of Stavudine; D 4T (nucleoside); Estavudina [INN-Spanish]; Sanilvudine (JAN); Stavudine, Monosodium Salt; Stavudinum [INN-Latin]; Zerit (TN); Zerit(TM); D4T & GM-CSF; D4TMBY-27857-3; Stavudine (USAN/INN); Stavudine [USAN:BAN:INN]; Stavudine [USAN:INN:BAN]; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-(7CI,8CI); 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; 2',3' Didehydro 3' deoxythymidine; 2',3'-Anhydrothymidine; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI); 2',3'-Didehydro-2',3'-dideoxythmidine; 2',3'-Didehydro-3'-deoxythimidine; 2',3'-Didehydro-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Deoxy-2',3'-didehydrothymidine; 3'-Deoxy-2'-thymidinene; D4T |
| Drug Type |
Small molecular drug |
| Therapeutic Class |
Anti-HIV Agents |
| Company |
Aurobindo Pharma |
| Structure |
|
| Drug Resistance Mutations |
| Target Name |
HIV Nucleoside reverse transcriptase |
Target Info |
| Uniprot ID |
POL_HV1B1(600-1159) |
| Species |
Human immunodeficiency virus type 1 (HIV-1) |
| Reference Sequence |
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV
FAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL
DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVI
YQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWT
VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE
LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGA
HTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTP
PLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTN [Human immunodefici
ency virus type 1 (HIV-1)]
|
| Targeted Disease |
HIV infection |
| Drug Resistance Mutations |
| Mutation info |
Missense: T215F |
[1], [2], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: D67N |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K219E |
[1], [2] |
|
| Mutation info |
Missense: K219Q |
[1], [2] |
|
| Mutation info |
Missense: K65N |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: K65R |
[1], [2] |
| Level of Resistance |
High-level resistance |
|
| Mutation info |
Missense: K70E |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70G |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70N |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70Q |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70R |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70S |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: K70T |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: L210W |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: M184* |
[1], [2] |
|
| Mutation info |
Missense: M41L |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: Q151L |
[1], [2] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: Q151M |
[1], [2] |
| Level of Resistance |
High-level resistance |
|
| Mutation info |
Missense: T210W |
[1], [2] |
|
| Mutation info |
Missense: T215A |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215C |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215D |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215E |
[1], [2] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215I |
[1], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215L |
[1], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215N |
[1], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215S |
[1], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215V |
[1], [3] |
| Level of Resistance |
Low-level resistance |
|
| Mutation info |
Missense: T215Y |
[1], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: V75A |
[1], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: V75M |
[1], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: V75S |
[1], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Missense: V75T |
[1], [3] |
| Level of Resistance |
High-level resistance |
|
| Mutation info |
Missense: L74I |
[4] |
| Mutation Frequency |
3-20% of the samples |
|
| Target Name |
HIV Non-Nucleoside reverse transcriptase |
Target Info |
| Uniprot ID |
POL_HV1B1(600-1159) |
| Species |
Human immunodeficiency virus type 1 (HIV-1) |
| Reference Sequence |
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV
FAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL
DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVI
YQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWT
VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE
LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGA
HTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTP
PLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQ
AIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHK
GIGGNEQVDKLVSAGIRKIL [Human immunodeficiency virus type 1 (H
IV-1)]
|
| Targeted Disease |
HIV infection |
| Drug Resistance Mutations |
| Mutation info |
Deletion: D67 |
[1], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Deletion: K70 |
[1], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Deletion: S68 |
[1], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Insertion: T69 |
[1], [3] |
| Level of Resistance |
Intermediate resistance |
|
| Mutation info |
Deletion: T69 |
[1], [3] |
| Level of Resistance |
Intermediate resistance |
|
| References |
| REF 1 |
The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012;55(2):98-101.
|
| REF 2 |
Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. J Antimicrob Chemother. 2014 Aug;69(8):2032-42.
|
| REF 3 |
Personalized HIV therapy to control drug resistance. Drug Discov Today Technol. 2014 Mar;11:57-64.
|
| REF 4 |
Mechanisms of anti-retroviral drug resistance: implications for novel drug discovery and development. Infect Disord Drug Targets. 2013 Oct;13(5):330-6.
|
